Amylyx Pharmaceuticals (AMLX) said Tuesday that the US Food and Drug Administration has lifted a clinical hold on a phase 1 clinical trial of AMX0114, an amyotrophic lateral sclerosis treatment candidate.
The company said it is now in the process of opening US sites for screening, enrollment and dosing with the lifting of the clinical hold.
Amylyx said the lifting of the clinical hold comes as it expects to start a phase 1 clinical trial in Canada that will assess the safety and biological activity of AMX0114, adding that it anticipates early group data from the study this year.
Shares were down 5.2% ahead of Tuesday's opening bell.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。